Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Association of Plasminogen Activator Inhibitor Type 1 (PAI-1) Level and PAI-1 4G/5G Gene Polymorphism with the Formation and the Grade of Endometrial Cancer.

Biochemical genetics - 1 Aug 2017

Yıldırım Malik Ejder, Karakuş Savas, Kurtulgan Hande Küçük, Kılıçgün Hasan, Erşan Serpil, Bakır Sevtap

Abstract excerpt

Plasminogen activator inhibitor type 1 (PAI-1) is a serine protease inhibitor (Serpine 1), and it inhibits both tissue plasminogen activator and urokinase plasminogen activator which are important in fibrinolysis. We aimed to find whether there is a possible association between PAI-1 level, PAI-1 4G/5G polymorphism, and endometrial cancer. PAI-1 levels in peripheral blood were determined in 82 patients with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Endometrial Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Expression Regulation, Neoplastic

Share to Genetic Association Studies

Share to Neoplasm Grading

Share to Plasminogen Activator Inhibitor 1

Share to Polymorphism, Single Nucleotide

Share to Promoter Regions, Genetic

Source

Identifiers

PMID: 28303356
DOI: 10.1007/s10528-017-9796-7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Association of Plasminogen Activator Inhibitor Type 1 (PAI-1) Level and PAI-1 4G/5G Gene Polymorphism with the Formation and the Grade of Endometrial Cancer.PMID 28303356Read ↗

Plasminogen activator inhibitor-1 (PAI-1) 4 G/5 G polymorphism and endometrial cancer. Influence of PAI-1 polymorphism on tissue PAI-1 antigen and mRNA expression and tumor severity.Semantic proximity Read ↗

PAI-1 4G/5G polymorphism contributes to cancer susceptibility: evidence from meta-analysis.Semantic proximity Read ↗

Genetic polymorphism of the plasminogen activator inhibitor-1 is associated with an increased risk of endometrial cancer.Semantic proximity Read ↗

What is the impact of plasminogen activator inhibitor type 1 (PAI-1) gene polymorphism on gynecological malignancies: a retrospective studySemantic proximity Read ↗

Plasminogen activator inhibitor -1 gene 4G/5G polymorphism in patients with breast cancer.Semantic proximity Read ↗

Plasminogen activator inhibitor-1 4G/5G polymorphism in breast cancer patients and its association with tissue PAI-1 levels and tumor severity.Semantic proximity Read ↗

Clinicopathological significance of plasminogen activator inhibitor-1 promoter 4G/5G polymorphism in breast cancer: a meta-analysis.Semantic proximity Read ↗

Clinical impact of PAI 1 4G/5G gene polymorphism in colorectal carcinoma patients.Semantic proximity Read ↗

Plasminogen activator inhibitor 1 (PAI-1) levels and gene promoter polymorphisms in subjects with colorectal cancer.Semantic proximity Read ↗

Plasminogen activator inhibitor-1 gene polymorphism and colorectal cancer risk and prognosis.Semantic proximity Read ↗

PAI-1 Polymorphisms Have Significant Associations With Cancer Risk, Especially Feminine Cancer.Semantic proximity Read ↗

Association between Five Common Plasminogen Activator Inhibitor-1 (PAI-1) Gene Polymorphisms and Colorectal Cancer Susceptibility.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.